Position in CGON
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$475,892
+$148,321 QoQ
Shares Held
6,698
+38.4% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#139
of 226 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in CGON Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Ameritas Investment Partners, Inc. holds $62,741,652 across 267 Biotechnology names. CGON ranks #27 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,422 | $6,170,379 | |
| 2 | EXEL |
Exelixis, Inc.
|
75,969 | $4,133,473 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
40,729 | $3,187,858 | |
| 4 | CYTK |
Cytokinetics Inc
|
36,992 | $3,151,348 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
83,064 | $2,939,634 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,593 | $2,863,919 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
11,547 | $2,782,480 | |
| 8 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
25,923 | $2,112,983 |
All Filings in CGON
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $475,892 | 6,698 | Shares | Other | 2026-08-13 | |
| 2026-03-31 | $327,571 | 4,840 | Shares | Other | 2026-05-13 | |
| 2025-12-31 | $193,815 | 4,668 | Shares | Other | 2026-02-11 | |
| 2025-09-30 | $188,027 | 4,668 | Shares | Other | 2025-11-10 | |
| 2025-06-30 | $142,350 | 5,475 | Shares | Other | 2025-08-12 | |
| 2025-03-31 | $134,082 | 5,475 | Shares | Other | 2025-05-12 | |
| 2024-12-31 | $137,807 | 4,805 | Shares | Other | 2025-02-13 | |
| 2024-09-30 | $181,292 | 4,805 | Shares | Other | 2024-11-13 | |
| 2024-06-30 | $73,242 | 2,320 | Shares | Other | 2024-08-13 | |
| 2024-03-31 | $101,848 | 2,320 | Shares | Other | 2024-05-13 | |
| No filing history on record for this holder in this stock. | ||||||